| A functional genomic screen identifies the deubiquitinase USP11 as a novel transcriptional regulator of ERα in breast cancer L Dwane, AE O'Connor, S Das, B Moran, L Mulrane, A Pinto-Fernandez, ... Cancer Research 80 (22), 5076-5088, 2020 | 18 | 2020 |
| Master transcription regulators and transcription factors regulate immune-associated differences between patients of African and European ancestry with Colorectal Cancer PA Myer, H Kim, AM Blümel, E Finnegan, A Kel, TV Thompson, JM Greally, ... Gastro Hep Advances 1 (3), 328-341, 2022 | 2 | 2022 |
| An Insight Into the Driver Mutations and Molecular Mechanisms Underlying Mucinous Adenocarcinoma of the Rectum IS Reynolds, E O’Connell, M Fichtner, A Blümel, SE Mason, J Kinross, ... Diseases of the Colon & Rectum 64 (6), 677-688, 2021 | 2 | 2021 |
| Assessment of tumour infiltrating subpopulations and pathological complete response using multiplex immunohistochemistry and digital pathology in early HER2+ breast cancer. C Hurley, L Lacroix, K Sheehan, M Lucas, R Buckley, A Blümel, S Toomey, ... Journal of Clinical Oncology 40 (16_suppl), e15041-e15041, 2022 | 1 | 2022 |
| CD45-positive tumor infiltrating lymphocytes in early-stage hormone-positive, HER2-negative (ER+/HER2-) breast cancer: Correlation with proliferation and prognostic signature … M Lucas, Z Kinsella, CA Gonzalez, C Hurley, A Blümel, J Fay, A O'Grady, ... Journal of Clinical Oncology 40 (16_suppl), e12555-e12555, 2022 | 1 | 2022 |
| Abstract PO2-24-04: Exploring the role and therapeutic potential of Ubiquitin Specific Peptidase 11 (USP11) in estrogen receptor positive breast cancer R Moore, A Blümel, E Ward, E Sainsbury, E Conroy, F O’Brien, C Curtin, ... Cancer Research 84 (9_Supplement), PO2-24-04-PO2-24-04, 2024 | | 2024 |
| Abstract PS16-10: SPATIAL IMMUNE CELL DISTRIBUTION CAN REFINE PROGNOSIS IN EARLY-STAGE ER+/HER2-/LN-BREAST CANCER Z Kinsella, H Nyarko, A Blümel, M Lucas, D Kalinska-Lysiak, CA Gonzalez, ... Cancer Research 84 (9_Supplement), PS16-10-PS16-10, 2024 | | 2024 |
| Abstract PO3-18-08: Rational therapeutic combination of Bromodomain and Extra-Terminal domain (BET) inhibitor and Fibroblast Growth Factor Receptor (FGFR) inhibitor for … B Gao, E Ward, A Blümel, E Conroy, R Moore, G Cremin, R Bleach, ... Cancer Research 84 (9_Supplement), PO3-18-08-PO3-18-08, 2024 | | 2024 |
| Complexation of histone deacetylase inhibitor belinostat to Cu(II) prevents premature metabolic inactivation in vitro and demonstrates potent anti-cancer activity in vitro and … E Finnegan, W Ding, Z Ude, S Terer, T McGivern, AM Blümel, G Kirwan, ... Cellular Oncology, 1-21, 2023 | | 2023 |
| Predictive modelling of response to neoadjuvant therapy in HER2+ breast cancer N Cosgrove, AJ Eustace, P O’Donovan, SF Madden, B Moran, J Crown, ... NPJ Breast Cancer 9 (1), 72, 2023 | | 2023 |
| Modelling the spatial heterogeneity of CD45-positive tumor infiltrating lymphocytes in early-stage, estrogen receptor-positive breast cancer Z Kinsella, A Blümel, M Lucas, A Lindner, CA Gonzalez, A Rahman, J Fay, ... Cancer Research 83 (7_Supplement), 5787-5787, 2023 | | 2023 |
| 41P The impact of tumour-infiltrating lymphocyte subpopulations on pathological complete response in HER2+ breast cancer C Hurley, L Lacroix, M Lucas, R Buckley, A Blümel, K Sheehan, S Toomey, ... Annals of Oncology 33, S141, 2022 | | 2022 |
| 38P Tumour-infiltrating lymphocytes and correlation with prognostic signature scores in early-stage hormone-positive, HER2-negative (ER+/HER2-) breast cancer MW Lucas, Z Kinsella, C Gonzalez, C Hurley, A Blümel, T O'Grady, ... Annals of Oncology 33, S140, 2022 | | 2022 |
| Abstract PD14-07: Bromodomain and Extra-Terminal motif (BET) inhibitors are a rational therapeutic choice for treatment of invasive lobular carcinoma E Ward, A Blümel, E Conroy, G Cremin, B Gao, W Gallagher, I Cruz, ... Cancer Research 82 (4_Supplement), PD14-07-PD14-07, 2022 | | 2022 |
